CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
- S&P 500, Dow close slightly up; Nvidia gains after the bell
- Nvidia guidance tops estimates as AI-led chip demand continues; shares jump
- More signs inflation is slowing before pivot to cuts as upside risks emerge: Fed
- Rivian production guidance falls short; shares slump
- Yields rise on Fed fears of cutting rates too soon, stocks mixed
The HOA forms a collaborative effort between CytoMed and CytoMed China to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells for the treatment of various cancers (including solid tumors) in human subjects through an investigator-initiated trial (IIT) in
"Initiating this IIT in collaboration with CytoMed in
Pursuant to the HOA, CytoMed will provide technical assistance in the planning and conduct of the clinical trial and will grant CytoMed China, a loan of up to an aggregate of
The HOA is a legally binding document and shall expire if approval for the IIT is not obtained by
"The recent approval of the Beijing Work Plan 2.0 demonstrates
In addition to this HOA, CytoMed has recently entered a MOU with BioNex Solutions Inc., a company incorporated/headquartered in
BioNex is a private company with patient-centric care facilities, targeting unmet medical needs in cancer treatment. BioNex specializes in the realm of cell therapy and is committed to pioneering advancements in the field.
Both the HOA and MOU were entered into just months after CytoMed announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, licensed exclusively to CytoMed from the Agency for Science, Technology and Research (A*STAR) of
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR),
Forward Look Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's expectations regarding the impact of the ongoing COVID-19 pandemic on its business, the Company's industry and the economy; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytomed-therapeutics-signs-hoa-and-mou-to-advance-research-on-allogeneic-gamma-delta-t-cell-technology-302005975.html
SOURCE CytoMed Therapeutics Limited
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chord Energy (CHRD), Enerplus (ERF) to merge in $11 billion deal
- Arkhouse Nominates Nine Directors to Macy's (M) Board
- Biofrontera Inc. (BFRI) Announces $16M Private Placement
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Related EntitiesTwitter, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!